Abstract
Poly(ethylene glycol)-polypeptide (PEG-polypeptide) based polymeric micelles as therapeutic agent carriers have received considerable interest due to their advanced achievements in clinical trials. Polypeptides not only show well-defined secondary structure (alfa-helix and beta-sheet) and good biocompatibility, but can also be functionalized with various groups by direct N-carboxyanhydrides (NCAs) polymerization or further modification. Additionally, the ionizable side chains enable them to deliver diverse therapeutic agents, such as negative nucleic acid and positive doxorubicin. In this review, we firstly summarized the synthetic methods of amphiphilic copolymers PEG-polypeptide, and emphatically discussed recent progress on their applications as nanocarriers for therapeutic agents from following aspects: PEG-nonionic polypeptide copolymer micelles, PEG-anionic polypeptide micelles, and PEGcationic polypeptide micelles.
Keywords: Polypeptide, poly(ethylene glycol), amphiphilic, micelles, therapeutic agents.
Current Pharmaceutical Biotechnology
Title:Poly(ethylene glycol)-polypeptide Copolymer Micelles for Therapeutic Agent Delivery
Volume: 17 Issue: 3
Author(s): Yilong Cheng
Affiliation:
Keywords: Polypeptide, poly(ethylene glycol), amphiphilic, micelles, therapeutic agents.
Abstract: Poly(ethylene glycol)-polypeptide (PEG-polypeptide) based polymeric micelles as therapeutic agent carriers have received considerable interest due to their advanced achievements in clinical trials. Polypeptides not only show well-defined secondary structure (alfa-helix and beta-sheet) and good biocompatibility, but can also be functionalized with various groups by direct N-carboxyanhydrides (NCAs) polymerization or further modification. Additionally, the ionizable side chains enable them to deliver diverse therapeutic agents, such as negative nucleic acid and positive doxorubicin. In this review, we firstly summarized the synthetic methods of amphiphilic copolymers PEG-polypeptide, and emphatically discussed recent progress on their applications as nanocarriers for therapeutic agents from following aspects: PEG-nonionic polypeptide copolymer micelles, PEG-anionic polypeptide micelles, and PEGcationic polypeptide micelles.
Export Options
About this article
Cite this article as:
Cheng Yilong, Poly(ethylene glycol)-polypeptide Copolymer Micelles for Therapeutic Agent Delivery, Current Pharmaceutical Biotechnology 2016; 17 (3) . https://dx.doi.org/10.2174/1389201017666151223124135
DOI https://dx.doi.org/10.2174/1389201017666151223124135 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Quinoline Based Sulfonamide Derivatives: Cytotoxic and Apoptotic Activity Evaluation Against Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity
Medicinal Chemistry Reviews - Online (Discontinued) Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Stem Cell-Like Brain Cancer Cells
Current Cancer Therapy Reviews Distinguished Photons: A Review of In Vivo Spectral Fluorescence Imaging in Small Animals
Current Pharmaceutical Biotechnology Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Advances of Bioinformatics Applied to Development and Evaluation of Boron-Containing Compounds
Current Organic Chemistry Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Microarray Data Analysis: Current Practices and Future Directions
Current Pharmacogenomics Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy
Current Drug Targets Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets Influence of Trishomocubanes on Sigma Receptor Binding of N-(1-Benzylpiperidin- 4-yl)-4-[123I]iodobenzamide In Vivo in the Rat Brain
Medicinal Chemistry Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery (Discontinued) Small Molecule Regulators Targeting NAD<sup>+ </sup>Biosynthetic Enzymes
Current Medicinal Chemistry Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design The Safety of the Temozolomide in Patients with Malignant Glioma
Current Drug Safety Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Role of ABC Transporters in the Chemoresistance of Human Gliomas
Current Cancer Drug Targets